Abstract

Mesenchimal stem cells (MSCs) have been used experimentally and clinically in the treatment of a wide variety of pathologies MSCs can be safely transplanted in autologous and allogenic ways as they are non-immunogenic, and consequently represent a therapeutic option for refractory connective tissue diseases, fibrosing diseases like scleroderma and fistulizing colitis like in Crohn's disease (CD). The immunomodulatory properties of MSCs have already shown promise when used as therapy for otherwise medically refractory CD. Accumulating evidence suggests that the properties may also be exploited of several other conditions. The currently available experimental and clinical data indicate that, similar to previously obtained data in the setting of HSCT, MSC treatment for IBD is feasible and safe. aim of this review is to analyze the pathophysiological insights for the use of MSCs in inflammatory bowel diseases, and to summarize the clinical evidences about the efficacy and safety of stem cell therapy in such disorders.
Lingua originaleEnglish
Numero di pagine0
RivistaINTERNATIONAL JOURNAL OF STEM CELL RESEARCH AND TRANSPLANTATION
Volume1
Stato di pubblicazionePublished - 2013

Fingerprint

Inflammatory Bowel Diseases
Stem Cells
Crohn Disease
Connective Tissue Diseases
Colitis
Therapeutics
Cell- and Tissue-Based Therapy
Pathology
Safety

Cita questo

@article{a75e1345193446ebb2661475c668a749,
title = "MESENCHIMAL STEM CELLS IN INFLAMMATORY BOWEL DISEASES: CLINICAL EVIDENCES AND POTENTIAL INSIGHTS FOR THE CLINICIANS",
abstract = "Mesenchimal stem cells (MSCs) have been used experimentally and clinically in the treatment of a wide variety of pathologies MSCs can be safely transplanted in autologous and allogenic ways as they are non-immunogenic, and consequently represent a therapeutic option for refractory connective tissue diseases, fibrosing diseases like scleroderma and fistulizing colitis like in Crohn's disease (CD). The immunomodulatory properties of MSCs have already shown promise when used as therapy for otherwise medically refractory CD. Accumulating evidence suggests that the properties may also be exploited of several other conditions. The currently available experimental and clinical data indicate that, similar to previously obtained data in the setting of HSCT, MSC treatment for IBD is feasible and safe. aim of this review is to analyze the pathophysiological insights for the use of MSCs in inflammatory bowel diseases, and to summarize the clinical evidences about the efficacy and safety of stem cell therapy in such disorders.",
author = "Giovanni Tomasello and Mario Cottone and Giuseppe Damiano and Palumbo, {Vincenzo Davide} and Gabriele Spinelli",
year = "2013",
language = "English",
volume = "1",
journal = "INTERNATIONAL JOURNAL OF STEM CELL RESEARCH AND TRANSPLANTATION",
issn = "2328-3548",

}

TY - JOUR

T1 - MESENCHIMAL STEM CELLS IN INFLAMMATORY BOWEL DISEASES: CLINICAL EVIDENCES AND POTENTIAL INSIGHTS FOR THE CLINICIANS

AU - Tomasello, Giovanni

AU - Cottone, Mario

AU - Damiano, Giuseppe

AU - Palumbo, Vincenzo Davide

AU - Spinelli, Gabriele

PY - 2013

Y1 - 2013

N2 - Mesenchimal stem cells (MSCs) have been used experimentally and clinically in the treatment of a wide variety of pathologies MSCs can be safely transplanted in autologous and allogenic ways as they are non-immunogenic, and consequently represent a therapeutic option for refractory connective tissue diseases, fibrosing diseases like scleroderma and fistulizing colitis like in Crohn's disease (CD). The immunomodulatory properties of MSCs have already shown promise when used as therapy for otherwise medically refractory CD. Accumulating evidence suggests that the properties may also be exploited of several other conditions. The currently available experimental and clinical data indicate that, similar to previously obtained data in the setting of HSCT, MSC treatment for IBD is feasible and safe. aim of this review is to analyze the pathophysiological insights for the use of MSCs in inflammatory bowel diseases, and to summarize the clinical evidences about the efficacy and safety of stem cell therapy in such disorders.

AB - Mesenchimal stem cells (MSCs) have been used experimentally and clinically in the treatment of a wide variety of pathologies MSCs can be safely transplanted in autologous and allogenic ways as they are non-immunogenic, and consequently represent a therapeutic option for refractory connective tissue diseases, fibrosing diseases like scleroderma and fistulizing colitis like in Crohn's disease (CD). The immunomodulatory properties of MSCs have already shown promise when used as therapy for otherwise medically refractory CD. Accumulating evidence suggests that the properties may also be exploited of several other conditions. The currently available experimental and clinical data indicate that, similar to previously obtained data in the setting of HSCT, MSC treatment for IBD is feasible and safe. aim of this review is to analyze the pathophysiological insights for the use of MSCs in inflammatory bowel diseases, and to summarize the clinical evidences about the efficacy and safety of stem cell therapy in such disorders.

UR - http://hdl.handle.net/10447/84523

UR - http://scidoc.org/articles%20pdf/ijst/IJST-01-301.pdf

M3 - Article

VL - 1

JO - INTERNATIONAL JOURNAL OF STEM CELL RESEARCH AND TRANSPLANTATION

JF - INTERNATIONAL JOURNAL OF STEM CELL RESEARCH AND TRANSPLANTATION

SN - 2328-3548

ER -